Ampersand Technologies
Ampersand Technologies is developing custom, precision genetic tests to enable evidence-based decision-making in horticulture, agriculture, biosecurity, and environmental monitoring. The technology has emerged as a challenger to PCR in the molecular diagnostics space and is already being used for point-of-need human medical diagnostics. Ampersand’s objective is to bring this technology to sectors that stand to benefit from using molecular diagnostics at the point-of-need, and to build a connected solution, providing a clear pathway to implementation for end users. Ampersand Technologies officially launched in August 2021. The start-up, which is being led by Dr. Richard Winkworth, received co-investment from Matū, a venture capital fund focused on early-stage science and technology, and Massey Ventures, the company responsible for commercialising innovative research at Massey University.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
2
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
2
organic / mo
Sign up free to see all 2 verified contacts at Ampersand Technologies
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Ampersand Technologies
2 distinct titles indexed · top 2 shown.
- 1board director
- 1lead data scientist
Sign up to unlock all 2 contacts at Ampersand Technologies
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Ampersand Technologies
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.